[Retherapy with lamivudine in hbeag-negative chronic hepatitis B patients unresponsive to interferon/peginterferon treatment].
The paper gives data on retherapy with lamivudine in seven HBeAg-negative chronic hepatitis B patients previously unresponsive to interferon-alpha and peginterferon-alpha2b therapy (6 unresponsive patients and 1 with recurrence). Prior to lamivudine therapy, hepatic biopsy and HBV genotyping were carried out and the baseline level of viremia and the presence of YMDD mutations were determined in all the patients. Its therapeutic efficiency was based on viremia level and AIAT activity at 6, 12, 18, and 24 weeks of treatment. Six of the 7 patients, including 2 receiving peginterferon-a2a, achieved a virological response. Trends in viremia within the first 12 weeks of treatment were a major factor to assess the virological response. Positive predictors during retreatment with lamivudine are discussed.